Alberto Pilotto1, Maria Cristina Polidori2, Nicola Veronese3, Francesco Panza4, Rosa Arboretti Giancristofaro5, Andrea Pilotto6, Julia Daragjati7, Eleonora Carrozzo8, Camilla Prete9, Pietro Gallina7, Alessandro Padovani6, Stefania Maggi10. 1. Geriatrics Unit, Department of Geriatric Care, OrthoGeriatrics and Rehabilitation, E.O. Galliera Hospital, National Relevance and High Specialization Hospital, Genova, Italy; Azienda ULSS 6 Euganea, S. Antonio Hospital, Padova, Italy. 2. Aging Clinical Research, Department II of Internal Medicine, University Hospital of Cologne, Cologne, Germany. 3. Geriatrics Unit, Department of Geriatric Care, OrthoGeriatrics and Rehabilitation, E.O. Galliera Hospital, National Relevance and High Specialization Hospital, Genova, Italy; National Research Council, Neuroscience Section, Padova, Italy. Electronic address: ilmannato@gmail.com. 4. Neurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience, and Sense Organs, University of Bari Aldo Moro, Bari, Italy; Department of Clinical Research in Neurology, University of Bari Aldo Moro, Pia Fondazione Cardinale G. Panico, Tricase, Lecce, Italy. 5. Department of Civil, Environmental and Architectural Engineering, University of Padua, Padua, Italy. 6. Neurology Department, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. 7. Azienda ULSS 6 Euganea, S. Antonio Hospital, Padova, Italy. 8. Department of Management and Engineering, University of Padova, Padova, Italy. 9. Geriatrics Unit, Department of Geriatric Care, OrthoGeriatrics and Rehabilitation, E.O. Galliera Hospital, National Relevance and High Specialization Hospital, Genova, Italy. 10. National Research Council, Neuroscience Section, Padova, Italy.
Abstract
OBJECTIVE: To evaluate whether treatment with antidementia drugs is associated with reduced mortality in older patients with different mortality risk at baseline. DESIGN: Retrospective. SETTING: Community-dwelling. PARTICIPANTS: A total of 6818 older people who underwent a Standardized Multidimensional Assessment Schedule for Adults and Aged Persons (SVaMA) evaluation to determine accessibility to homecare services or nursing home admission from 2005 to 2013 in the Padova Health District, Italy were included. MEASUREMENTS: Mortality risk at baseline was calculated by the Multidimensional Prognostic Index (MPI), based on information collected with the SVaMA. Participants were categorized to have mild (MPI-SVaMA-1), moderate (MPI-SVaMA-2), and high (MPI-SVaMA-3) mortality risk. Propensity score-adjusted hazard ratios (HR) of 2-year mortality were calculated according to antidementia drug treatment. RESULTS: Patients treated with antidementia drugs had a significant lower risk of death than untreated patients (HR 0.82; 95% confidence interval [CI] 0.73-0.92 and 0.56; 95% CI 0.49-0.65 for patients treated less than 2 years and more than 2 years treatment, respectively). After dividing patients according to their MPI-SVaMA grade, antidementia treatment was significantly associated with reduced mortality in the MPI-SVaMA-1 mild (HR 0.71; 95% CI 0.54-0.92) and MPI-SVaMA-2 moderate risk (HR 0.61; 95% CI 0.40-0.91, matched sample), but not in the MPI-SVaMA-3 high risk of death. CONCLUSIONS: This large community-dwelling patient study suggests that antidementia drugs might contribute to increased survival in older adults with dementia with lower mortality risk.
OBJECTIVE: To evaluate whether treatment with antidementia drugs is associated with reduced mortality in older patients with different mortality risk at baseline. DESIGN: Retrospective. SETTING: Community-dwelling. PARTICIPANTS: A total of 6818 older people who underwent a Standardized Multidimensional Assessment Schedule for Adults and Aged Persons (SVaMA) evaluation to determine accessibility to homecare services or nursing home admission from 2005 to 2013 in the Padova Health District, Italy were included. MEASUREMENTS: Mortality risk at baseline was calculated by the Multidimensional Prognostic Index (MPI), based on information collected with the SVaMA. Participants were categorized to have mild (MPI-SVaMA-1), moderate (MPI-SVaMA-2), and high (MPI-SVaMA-3) mortality risk. Propensity score-adjusted hazard ratios (HR) of 2-year mortality were calculated according to antidementia drug treatment. RESULTS:Patients treated with antidementia drugs had a significant lower risk of death than untreated patients (HR 0.82; 95% confidence interval [CI] 0.73-0.92 and 0.56; 95% CI 0.49-0.65 for patients treated less than 2 years and more than 2 years treatment, respectively). After dividing patients according to their MPI-SVaMA grade, antidementia treatment was significantly associated with reduced mortality in the MPI-SVaMA-1 mild (HR 0.71; 95% CI 0.54-0.92) and MPI-SVaMA-2 moderate risk (HR 0.61; 95% CI 0.40-0.91, matched sample), but not in the MPI-SVaMA-3 high risk of death. CONCLUSIONS: This large community-dwelling patient study suggests that antidementia drugs might contribute to increased survival in older adults with dementia with lower mortality risk.
Authors: Alberto Pilotto; Alberto Cella; Andrea Pilotto; Julia Daragjati; Nicola Veronese; Clarissa Musacchio; Anna Maria Mello; Giancarlo Logroscino; Alessandro Padovani; Camilla Prete; Francesco Panza Journal: J Am Med Dir Assoc Date: 2016-12-31 Impact factor: 4.669
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Alberto Pilotto; Pietro Gallina; Andrea Fontana; Daniele Sancarlo; Salvatore Bazzano; Massimiliano Copetti; Stefania Maggi; Giulia Paroni; Francesco Marcato; Fabio Pellegrini; Daniele Donato; Luigi Ferrucci Journal: J Am Med Dir Assoc Date: 2013-02-09 Impact factor: 4.669
Authors: Joshua D Niznik; Xinhua Zhao; Meiqi He; Sherrie L Aspinall; Joseph T Hanlon; Laura C Hanson; David Nace; Joshua M Thorpe; Carolyn T Thorpe Journal: J Am Geriatr Soc Date: 2019-11-26 Impact factor: 5.562
Authors: Alberto Pilotto; Carlo Custodero; Stefania Maggi; Maria Cristina Polidori; Nicola Veronese; Luigi Ferrucci Journal: Ageing Res Rev Date: 2020-03-21 Impact factor: 10.895
Authors: T Möllers; L Perna; H Stocker; P Ihle; I Schubert; B Schöttker; L Frölich; J Bauer; H Brenner Journal: Epidemiol Psychiatr Sci Date: 2019-11-14 Impact factor: 6.892
Authors: Alberto Pilotto; Nicola Veronese; Katerin Leslie Quispe Guerrero; Sabrina Zora; An L D Boone; Matteo Puntoni; Angela Giorgeschi; Alberto Cella; Ines Rey Hidalgo; Yves-Marie Pers; Alberto Ferri; Jose Ramon Hevia Fernandez; Marta Pisano Gonzalez Journal: Rejuvenation Res Date: 2018-12-28 Impact factor: 4.663